For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.
Exceeds the Upper End of Guidance Range for Full-Year 2024 with Unaudited Global Revenues of Approximately $363.7 Million-- --2025 Global ARIKAYCE Revenues Expected to be Between $405 Million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback